Please provide your email address to receive an email when new articles are posted on . Gerds, assistant professor of medicine at Cleveland Clinic Taussig Cancer Institute, discussed the study, that ...

While in nursing school, a patient recognized potential signs of a blood disorder and advocated for further testing, leading to an early diagnosis of essential thrombocythemia. Despite initial ...

A high platelet count can lead to blood clots and bleeding, which can be dangerous. Reactive thrombocytosis is often linked to another condition like an infection or inflammation and usually resolves ...

Patients with essential thrombocythemia faced an average delay of 26.5 months between their first high platelet count and diagnosis. Patients experienced a significant delay in receiving an essential ...

To the authors’ knowledge, the study is the first to include a patient with essential thrombocythemia (ET) and MPL and Type 1 calreticulin gene mutations. Authors of a case study suggest screening for ...

Hemorrhagic events post-diagnosis in patients with ET significantly increase mortality risk, more than thrombosis or disease progression. Intracranial hemorrhage is the most lethal bleeding ...

LOUISVILLE, Ky.--(BUSINESS WIRE)--Onco360 ®, the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by GlaxoSmithKline for OJJAARA™ (momelotinib). OJJAARA is a ...

WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte (Nasdaq:INCY) today announced the first clinical data from two studies evaluating the safety, tolerability and efficacy of INCA033989, a novel, first in ...

If you have the JAK2 V617F mutation, are aged 18-74 years old, do not smoke, do not have any known autoimmune disease, and attend medical checks at UAB regularly, you may be eligible for our study!